Identifying causing mechanisms in cancers with unknown primary site improves treatment & survival
Dr Zoran Gatalica discuss identifying the molecular profile of a tumour where the primary site is unknown and how it is crucial to the choice of treatment.
In up to five percent of all cancers, the site of the primary tumour is unknown and the disease is not diagnosed until it is at an advanced stage, when the cancer has metastasised (spread to other parts of the body).
Until recently, the choice of treatment has been based on efforts to find biomarkers that could indicate the site of origin, but now a team of researchers has succeeded in identifying the particular molecular profiles of the metastatic tumours in a large group of patients.
Видео Identifying causing mechanisms in cancers with unknown primary site improves treatment & survival канала ecancer
In up to five percent of all cancers, the site of the primary tumour is unknown and the disease is not diagnosed until it is at an advanced stage, when the cancer has metastasised (spread to other parts of the body).
Until recently, the choice of treatment has been based on efforts to find biomarkers that could indicate the site of origin, but now a team of researchers has succeeded in identifying the particular molecular profiles of the metastatic tumours in a large group of patients.
Видео Identifying causing mechanisms in cancers with unknown primary site improves treatment & survival канала ecancer
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metas...Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLCBreast cancer prevention in high-risk post-menopausal womenRegional lymph node irradiation in early breast cancerLatest advances in mHSPC from ASCO GU 2020ESMO 2017: Prostate cancer highlightsTargeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humansBreast cancer highlights from ASCO 2019Durvalumab following chemoradiotherapy improves survival in patients with limited-stage small-ce...The CAR T cell revolution in cancer therapyPhase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patientsCLL14: Venetoclax plus obinutuzumab in untreated CLLProstate cancer patients receiving androgen-deprivation therapies shown to be at lower risk from...Managing the side effects of CAR T-cell therapyLUMINA results: Women with low levels of the Ki67 biomarker can avoid outcomes related to RTMaintenance chemotherapy extends life for children with rare rhabdomyosarcomaAdvances in prostate cancer in the last 10 years and a glimpse to the futureHolistic management of patients with ALK-positive NSCLCMaster pathways and targets in T cell acute lymphoblastic leukaemiaElacestrant significantly prolongs PFS for ER+/HER2- metastatic BC without prior chemotherapy ptsThe role of lymph nodes in stage 3 lung cancer